Equity Overview
Price & Market Data
Price: $0.121
Daily Change: +$0.121 / 99.83%
Daily Range: $0 - $0
Market Cap: $205,088
Daily Volume: 0
Performance Metrics
1 Week: 60,400%
1 Month: 60,400%
3 Months: 60,400%
6 Months: 8,543%
1 Year: 8,543%
YTD: 8,543%
Details
RegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of therapeutic peptide, Thymosin beta 4, for tissue and organ protection, repair, and regeneration. The company is developing RGN-259, a preservative-free topical eye drop for regeneration of corneal tissues damaged by injury, disease, or other pathology; RGN-352, an injectable formulation for the treatment of cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications; and RGN-137, a topical gel for the treatment of dermal wounds and reduction of scar tissue. It has strategic partnerships with Lee's Pharmaceutical Group and HLB Therapeutics. The company was formerly known as Alpha 1 Biomedicals, Inc. and changed its name to RegeneRx Biopharmaceuticals, Inc. in 2000. RegeneRx Biopharmaceuticals, Inc. was incorporated in 1982 and is based in Rockville, Maryland.